03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
19:10 , Jun 14, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays A strain of E. coli engineered to express a synthetic gene circuit that detects the reactive oxygen species (ROS)-derivative tetrathionate could be used to diagnose intestinal inflammation in vivo. The synthetic gene circuit...
22:30 , Mar 16, 2017 |  BC Innovations  |  Targets & Mechanisms

Bone appétit!

Last week’s Nature publication of a hormone secreted by bone that suppresses appetite and can curb weight gain not only adds to the emerging picture of bone as a player in the endocrine system but...
12:54 , Mar 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity Mouse studies suggest LCN2 could help treat obesity. In a mouse model of obesity, LCN2 decreased food intake, body fat mass and weight gain compared with vehicle. Next steps include longer-term studies to evaluate...
18:52 , Jan 12, 2017 |  BC Innovations  |  Translation in Brief

Iron age arms race

Two research groups have turned bacteria’s own survival mechanisms against them with therapeutic vaccines based on siderophores - iron-scavenging molecules the pathogens secrete that are not ordinarily immunogenic. The preclinical studies showed conjugating siderophores to...
19:59 , Dec 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Hematology Mouse studies suggest an NGAL-enterobactin complex could help treat iron overload caused by chronic blood transfusion, hemochromatosis and other disorders. The complex consisted of the iron-chelating molecule enterobactin bound to a human NGAL variant...
07:00 , Jul 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Lipocalin (NGAL; LCN2)

Cancer INDICATION: Breast cancer Mouse studies suggest inhibiting NGAL could help treat breast cancer. In a mouse model of metastatic breast cancer, systemic NGAL knockout decreased the number of metastases in the lungs and levels of a...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

NGAL Test regulatory update

BioPorto said it will continue to seek FDA approval of its NGAL Test to detect acute kidney injury following discussions with the agency and anticipates “approval within 18-24 months.” In late May, FDA rejected the...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Clinical News

NGAL Test regulatory update

FDA rejected a regulatory application from BioPorto for the NGAL Test to detect acute kidney injury. According to the company, FDA rejected it because the application “did not provide adequate clinical and analytical data to...
08:00 , Feb 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Lipocalin (NGAL; LCN2)

Renal disease INDICATION: Renal Patient sample and mouse studies suggest 4-phenylbutyric acid could help treat proteinuria associated with chronic kidney disease. Renal tubule levels of NGAL were higher in patients with proteinuric nephropathy and mouse models of...